Description: Omalizumab is an IgG monoclonal antibody that reduces allergic response.

  • For treament of moderate to severe asthma
    • Blocks immune system’s response to allergic triggers to control asthma better
  • For ongoing hives from an unknown cause (chronic idiopathic urticaria-CIU) in adults and children over 12 years of age
    • Helps to reduce itching and number of hives on your skin
  • Does not have immediate effects and and should not be used for the quick relief of an acute asthma attack.

How to use omalizumab subcutaneous

  • Always refer to your doctors instructions before taking this medication. Duration and dosage will be determined by your medical condition and its response to the medication. Make sure to take this medication in the prescribed amount and time period even after symptoms disappear. Discontinuing the medication before completion of treatment may cause incomplete treatment of condition. If Symptoms persist, consult your doctor.
  • Injected under the skin (subcutaneously-SC) by a health care professional, usually every 2 or 4 weeks as directed by your doctor
  • May cause a very serious (sometimes fatal) allergic reaction
    • Usually occurs on the first dose but can occur in the succeeding doses within 24 hours or up to 4 days after receiving this medication
    • This type of reaction usually occurred within 24 hours or up to 4 days after receiving this medication. Close monitoring will be done by your health care professional during treatment for any signs of an allergic reaction
  • Never use again if you have a previous allergic reaction
  • Minor side effects (if these symptoms persist or worsen, inform your doctor)
    • Injection site itching, redness, stinging, or pain
    • Headache, leg, arm or ear pain
  • Serious side effects (inform your doctor immediately)
    • Unusual lumps/growths/moles
  • Very Serious Side effects (Get immediate Medical Assistance)
    • Chest/jaw/left arm pain
    • Unusual sweating
    • Sudden/severe headache
    • Weakness on one side of the body
    • Confusion
    • Trouble speaking
    • Sudden vision changes (such as partial/complete blindness)
    • pain/redness/swelling of legs, tingling/weakness/numbness in the arms/legs
    • Trouble breathing
    • Coughing up blood
    • Sudden dizziness/fainting.
  • Severe allergic reactions are rare. Get immediate medical help if you notice the following:
    • Rash, hives, itching/swelling (especially of the face/tongue/throat), dizziness, chest tightness, cough, trouble breathing.


  • Inform your doctor if you
    • Are allergic to the medication
  • If you are planning to be pregnant or think you may be pregnant, discuss the risks and benefits of use with your doctor.



Taking multiple drugs may affect how medications work and/or cause unwanted side effects. List down all the medications you are taking and inform your physician and pharmacist. Do not take, discontinue, or alter any dose of medications without prior approval of your physician.


If overdose is suspected, contact a poison control center or emergency room immediately.


Keep all medical appointments. Laboratory and/or medical tests may be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details.

Missed Dose

For the best possible benefit, it is important to receive each scheduled dose of this medication as directed. If you miss a dose, contact your doctor or pharmacist immediately to establish a new dosing schedule.


Not applicable. This medication is given in a clinic or doctor’s office and will not be stored at home.



Available Brands:

Xolair [ Novartis Healthcare ]

Related Articles


Xeomin (incobotulinumtoxinA) is a prescription medication that belongs to a class of drugs known as neurotoxins. It is derived from [...]


WONCARE is a ointment is made to be put directly on skin and wounds. It treats skin and wound infections, [...]


Vamocef is a broad-spectrum antibiotic belonging to the cephalosporin class. It is commonly prescribed to treat a variety of bacterial [...]